Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Are Evergreen Funds Too Good to be True? Michelle Celarier OCIOs: U.S. Stocks Are Expensive, But Don’t Trim Yet James Comtois Fireside Chat- Building Blocks: How Institutions Can Win With ETFs Sponsored by Northern Trust Asset Management